|On the cover: On the cover: Vivid life is everywhere in this blue planet. In this cover, four seasons are illustrated with diverse lives that are the traces of entire ecosystem circle. What a natural harmony! From birth to death, each species has its own life cycle and innate mechanisms decoded and to be decoded by scientists. The destiny of life cycle can be revealed by genome within a cell as the core of living beings. The more scientific discoveries about the core, the higher possibilities to disclose the truth of life. For sustainable development of our planet, it is important to build up one co-existing ecosystem for all living things.|
|Add comment (English only)|
|Position: Home > issue > January 25, 2022 Volume 3, Issue 1|
|China enters CAR-T cell therapy era|
|Category: News & Buzz Download: PDF Figure Endnote|
|Author: Xin Cao, Wei Li, Yiyi Yu, Tianshu Liu, Yuhong Zhou|
A brief diagram of CAR-T therapy
The emerging individualized and living-cell-based genetic engineering chimeric antigen receptor T (CAR-T) therapy demonstrates great curative effects in some hematological tumor treatments, thus it is turning out to be a star immunotherapy method of the world.1 Recently, the China National Medical Products Administration (NMPA) approved launching applications of two CAR-T cell cancer products, Axicabtagene Ciloleucel (FKC876) and Relmacabtagene Autoleucel (Carteyva), which marked the beginning of the of CAR-T cell therapy era in China (Figure 1).
Cao X., Li W., Yu Y., et al. (2021). China enters CAR-T cell therapy era. The Innovation. 3(1),100197.